This Week in Psychedelics

Congress forms a bi-partisan caucus to promote research into and awareness of psychedelics; plus how psychedelics could help treat anorexia.

March 3, 2023

This Week...

The Financial Times ran an in-depth story on how psychedelics could potentially treat anorexia.  

The idea of treating anorexia with psychedelics is not new, as researchers at Johns Hopkins University recently recruited volunteers with anorexia nervosa to participate in a research study that will investigate the psychological effects of psilocybin, including whether or not it can help with anorexia.

Those results aren’t available yet, but you can read more about how psychedelics could ultimately serve as a viable treatment for people suffering from anorexia here:

A bipartisan pair of federal lawmakers rebranded and relaunched a congressional caucus to promote research into and awareness around psychedelic-assisted therapy, hoping to shine a light on the practice’s potential to treat a variety of mental health conditions.

The renamed Congressional Psychedelics Advancing Therapies (PATH) Caucus intends to educate lawmakers on the growing evidence from leading research institutions that therapy involving substances like psilocybin and MDMA can help effectively treat PTSD, depression, and substance use disorder.

The group’s founders, Reps. Lou Correa (D-CA) and Jack Bergman (R-MI), said the caucus will also push for more federal research funding and convene bipartisan thought leaders to brief Congress on scientific evidence around psychedelics. Here’s more:

Ever wonder what the inside of a psychedelic therapy clinic looks like? Vice ran a piece this week that offered a look inside a legal psychedelic therapy clinic at St Charles Hospital in North Kensington where patients are taking psilocybin in a bid to treat mental disorders such as OCD. Check it out:

Did You Know?

Did you know that psychedelics could potentially treat depression by actually invading brain cells?  

According to a new study, psychedelics can access receptors inside cells that standard antidepressants usually can’t affect. Apparently, the drugs may be able to slip through the outer membranes of brain cells and essentially flip switches inside the cells that other depression treatments can't. Check it out: